What it is
Beckley Psytech is the company behind BPL-003, the intranasal 5-MeO-DMT benzoate program SCM tracks next to GH Research’s GH001 program.
For SCM readers, Beckley Psytech belongs in the company/program layer: sponsor, formulation, trial record, and company-readout language all need to stay attached to the BPL-003 asset rather than generic 5-MeO-DMT shorthand.
SCM-relevant program
The near-term SCM use case is BPL-003. Treatment-resistant depression is the main comparison lane with GH001. Alcohol-use disorder is an adjacent BPL-003 program context that can clarify breadth without expanding the map into every atai or Beckley asset.
When covering Beckley Psytech, the reader should be able to see which sentence comes from a company release, which comes from a registry, and which comes from peer-reviewed literature if a paper is pinned.
Guardrail
Do not treat Beckley Psytech, atai, BPL-003, 5-MeO-DMT, and GH001 as interchangeable labels. Company relationship, asset name, compound layer, route/formulation, indication, and evidence tier are separate facts.